Medifast (MED) Tops Q3 EPS by 63c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts MED Hot Sheet
Price: $12.17 +0.58%
Revenue Growth %: -24.3%
Financial Fact:
Income from operations: 8.95M
Today's EPS Names:
ORPB, PBCO, SICP, More
Revenue Growth %: -24.3%
Financial Fact:
Income from operations: 8.95M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
Medifast (NYSE: MED) reported Q3 EPS of $0.35, $0.63 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $140.2 million versus the consensus estimate of $134.15 million.
GUIDANCE:
Medifast sees Q4 2024 EPS of ($0.10)-($0.65), versus the consensus of ($0.14). Medifast sees Q4 2024 revenue of $100-120 million, versus the consensus of $131.7 million.
For earnings history and earnings-related data on Medifast (MED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Consumer Portfolio Services (CPSS) Reports Q3 EPS of $0.30
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
